MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof

Abstract

Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.1

We claim:  
     
         1 . Isolated cDNA molecule which encodes MAGE-10 tumor rejection antigen precursor, the complementary sequence of which hybridizes to nucleotides 164-574 SEQ ID NO: 3, under stringent conditions.  
     
     
         2 . The isolated cDNA molecule of  claim 1 , comprising nucleotides 67-2559 of SEQ ID NO: 3.  
     
     
         3 . The isolated cDNA molecule of  claim 1 , comprising SEQ ID NO: 3.  
     
     
         4 . Expression vector comprising the isolated cDNA molecule of  claim 1 , operably linked to a promoter.  
     
     
         5 . Eukaryotic cell line or prokaryotic cell strain, transfected or transformed with the expression of  claim 3 .  
     
     
         6 . Isolated MAGE-10 tumor rejection antigen precursor having a molecular weight of about 72 kilodaltons as determined by SDS-PAGE.  
     
     
         7 . Isolated MAGE-10 tumor rejection antigen precursor encoded by the isolated cDNA molecule of  claim 1 .  
     
     
         8 . Monoclonal antibody which binds to the isolated tumor rejection antigen precursor of  claim 6 .  
     
     
         9 . Isolated tumor rejection antigen precursor derived peptide consisting of the amino acid sequence of SEQ ID NO: 4.  
     
     
         10 . Immunogenic composition comprising the isolated MAGE-10 tumor rejection antigen precursor of  claim 6 , and an adjuvant.  
     
     
         11 . Immunogenic composition comprising the peptide of  claim 9  and an adjuvant.  
     
     
         12 . Polyclonal antiserum obtained by immunizing a non-human animal with the peptide of  claim 8  under conditions favoring an immune response thereto, and isolating antiserum produced thereby.  
     
     
         13 . Method for determining presence of MAGE-10 tumor rejection antigen precursor in a sample, comprising contacting said sample with the monoclonal antibody of  claim 8  and determining binding therebetween.  
     
     
         14 . Method for determining presence of MAGE-10 tumor rejection antigen precursor in a sample comprising contacting said sample with the polyclonal antiserum of  claim 12 , and determining binding therebetween.  
     
     
         15 . Hybridoma cell in which produces the monoclonal antibody of  claim 8 .  
     
     
         16 . The monoclonal antibody of  claim 8 , wherein said antibody is humanized.